Home | Publications | Healthcare place holder
place holder place holder

Healthcare

Bristol-Myers Squibb Co.: PharmaVitae Profile


Publication Date   July 2008
Publisher   Datamonitor
Product Type   Report
Pages   157
ISBN Number   not applicable
Product Code   DAT1468
Ask a question about this product?

Price £2,995.00

approximately: $4,466 | €3,568

Summary


Introduction

This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Bristol-Myers Squibb's performance against key rivals in the ethical pharmaceutical sector
  • Assess the level of generic exposure faced by Bristol-Myers Squibb out to 2013, driven primarily by patent expiry for its lead product Plavix in 2011
  • Analyze BMS's biologics-led growth strategy out to 2013, driven by its existing access to Erbitux and Orencia and new biologic launches also

Content


  • Table Of Tables
    • Table 1: Bristol-Myers Squibb - Pharmavitae Forecasts At A Glance
    • Table 2: Plavix Demise Set To Override 2007-13 Growth Prospects
    • Table 3: Bms''s Therapeutic Transformation ($M), 2007-13
    • Table 4: Bristol-Myers Squibb Key Product Developments, Q1-Q2 2008
    • Table 5: Bristol-Myers Squibb Product Deals And Alliances, Q1-Q2 2008
    • Table 6: Bristol-Myers Squibb Technology Deals And Alliances, Q1-Q2 2008
    • Table 7: Bristol-Myers Squibb M&A Activity, Q1-Q2 2008
    • Table 8: Bristol-Myers Squibb Company Announcements, Q1-Q2 2008
    • Table 9: Bristol-Myers Squibb Future Product Milestones, 2008-10
    • Table 10: Bristol-Myers Squibb Product Portfolio Overview ($M), 2001-07
    • Table 11: Bristol-Myers Squibb Product Portfolio Overview ($M), 2007-13
    • Table 12: Bristol-Myers Squibb Therapy Portfolio Overview ($M), 2001-07
    • Table 13: Bristol-Myers Squibb Therapy Portfolio Overview ($M), 2007-13
    • Table 14: Bristol-Myers Squibb Portfolio Overview By Geographic Region ($M), 2001-07
    • Table 15: Bristol-Myers Squibb Portfolio Overview By Geographic Region ($M), 2007-13
    • Table 16: Bristol-Myers Squibb Launch Portfolio Overview ($M), 2007-13
    • Table 17: Bristol-Myers Squibb Core Portfolio Overview ($M), 2007-13
    • Table 18: Bristol-Myers Squibb Expiry Portfolio Overview ($M), 2007-13
    • Table 19: Bristol-Myers Squibb Portfolio Overview By Molecule Type ($M), 2001-07
    • Table 20: Bristol-Myers Squibb Product Portfolio Overview By Molecule Type ($M), 2007-13
    • Table 21: Bristol-Myers Squibb Product Portfolio Overview By Source ($M), 2001-07
    • Table 22: Bristol-Myers Squibb Product Portfolio Overview By Source ($M), 2007-13
    • Table 23: Total Bristol-Myers Squibb Sales By Business Unit ($M), 2001-07
    • Table 24: Bristol-Myers Squibb Profit And Loss Account ($M), 2001-07
    • Table 25: Bristol-Myers Squibb Balance Sheet ($M), 2001-07
    • Table 26: Bristol-Myers Squibb Operating Revenue/Cost Analysis ($M), 2001-07
    • Table 27: Bristol-Myers Squibb Operating Cost Ratio Analysis (% Of Total Revenues), 2001-07
    • Table 28: Bristol-Myers Squibb Operating Cost Ratio Analysis (% Of Total Revenues), 2007-13
    • Table 29: Bristol-Myers Squibb Operating Revenue/Cost Analysis ($M), 2007-13
    • Table 30: Bristol-Myers Squibb Capital Employed ($M), 2001-07
    • Table 31: Bristol-Myers Squibb Ebit Return On Capital Employed ($M), 2001-07
    • Table 32: Bristol-Myers Squibb Ebit Pre-Tax Return/Capital Employed Driver Analysis (%), 2001-07
    • Table 33: Bristol-Myers Squibb Market Capitalization ($ Billion), 2001-07
    • Table 34: Bristol-Myers Squibb Total Shareholder Returns (Annual %), 2001-07
    • Table 35: Key Products Overview
    • Table 36: Erbitux: Overview
    • Table 37: Erbitux: Sales Forecast ($M), 2007-13
    • Table 38: Sprycel: Overview
    • Table 39: Sprycel: Sales Forecast ($M), 2007-13
    • Table 40: Ixempra: Overview
    • Table 41: Ixempra: Sales Forecast ($M), 2007-13
    • Table 42: Sustiva Franchise: Overview
    • Table 43: Sustiva Franchise: Sales Forecast ($M), 2007-13
    • Table 44: Reyataz: Overview
    • Table 45: Reyataz: Sales Forecast ($M), 2007-13
    • Table 46: Orencia: Overview
    • Table 47: Orencia: Sales Forecast ($M), 2007-13
    • Table 48: Plavix: Overview
    • Table 49: Plavix: Sales Forecast ($M), 2007-13
    • Table 50: Abilify: Overview
    • Table 51: Abilify: Sales Forecast ($M), 2007-13
    • Table 52: Onglyza: Overview
    • Table 53: Onglyza: Sales Forecast ($M), 2007-13
    • Table 54: Bristol-Myers Squibb''s R&D Pipeline (Phase I-registration)
    • Table 55: Exchange Rates, 2007
  • Table Of Figures
    • Figure 1: Bristol-Myers Squibb Prescription Pharmaceutical Performance, Sales ($M) And Growth Rate (%), 2001-13
    • Figure 2: Bristol-Myers Squibb''s Financial Performance ($M), 2001-13
    • Figure 3: Plavix Sales Dependency (% Of Total), 2001-13
    • Figure 4: Bristol-Myers Squibb Prescription Pharma Sales By Therapy Area (% Of Total), 2001-13
    • Figure 5: Bristol-Myers Squibb Swot Analysis
    • Figure 6: Current Corporate Structure
    • Figure 7: Bristol-Myers Squibb Prescription Pharmaceutical Performance, Sales ($M) And Growth Rate (%), 2001-13
    • Figure 8: Bristol-Myers Squibb Key Sales Growth Driver & Resistors ($M), 2001-07
    • Figure 9: Bristol-Myers Squibb Key Sales Growth Drivers & Resistors ($M), 2007-13
    • Figure 10: Bristol-Myers Squibb Prescription Pharmaceutical Sales By Therapy Area ($M), 2001-13
    • Figure 11: Bristol-Myers Squibb Prescription Pharma Sales By Therapy Area (% Of Total), 2001-13
    • Figure 12: Bristol-Myers Squibb Prescription Pharmaceutical Sales By Geographic Region ($M), 2001-13
    • Figure 13: Bristol-Myers Squibb Drivers And Resistors By Geographic Region ($M), 2001-07
    • Figure 14: Bristol-Myers Squibb Drivers And Resistors By Geographic Region ($M), 2007-13
    • Figure 15: Bristol-Myers Squibb Prescription Pharmaceutical Sales By Geographic Region (% Of Total), 2001-13
    • Figure 16: Bristol-Myers Squibb Launch/Core/Expiry Configuration ($M), 2007-13
    • Figure 17: Bristol-Myers Squibb Prescription Pharmaceutical Sales By Molecule Type ($M), 2001-13
    • Figure 18: Bristol-Myers Squibb Growth Drivers & Resistors By Molecule Type ($M), 2007-13
    • Figure 19: Bristol-Myers Squibb Prescription Pharmaceutical Sales By Source ($M), 2001-13
    • Figure 20: Bristol-Myers Squibb Growth Drivers & Resistors By Source ($M), 2001-07
    • Figure 21: Bristol-Myers Squibb Growth Drivers & Resistors By Source ($M), 2007-13
    • Figure 22: Bristol-Myers Squibb Operating Revenue/Cost Analysis ($M), 2001-13
    • Figure 23: Bristol-Myers Squibb Operating Cost Ratio Analysis (% Of Total Revenues), 2001-13
    • Figure 24: Bristol-Myers Squibb Return On Capital Employed, Ebit Margin And Capital Turnover, 2001-07
    • Figure 25: Return On Capital Employed Formula
    • Figure 26: Bristol-Myers Squibb Market Capitalization ($ Billion), 2001-07
    • Figure 27: Bristol-Myers Squibb Total Shareholder Returns Vs. S&P 500 ($M), 2001-07